Quillan Huang

Jan 6, 2025 | digitalcommons.library.tmc.edu | Quillan Huang |Irene Mitsiades |Heidi Dowst |Neda Zarrin-Khameh

AbstractThe rising utilization of circulating tumor DNA (ctDNA) assays in Precision Oncology may incidentally detect genetic material from secondary sources. It is important that such findings are recognized and properly leveraged for both diagnosis and monitoring of response to treatment.